L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

被引：1

作者：

Duell, Johannes ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Liberati, Anna Marina ^{[3
]}

Halka, Janusz ^{[4
]}

Carbo, Esther Pena ^{[5
]}

Costa, Pau Abrisqueta ^{[6
]}

Maddocks, Kami J. ^{[7
]}

Dreyling, Martin ^{[8
]}

Rosenwald, Andreas ^{[9
]}

Bakuli, Abhishek ^{[10
]}

Amin, Aasim ^{[10
]}

Gurbanov, Konstantin ^{[10
]}

Salles, Gilles ^{[11
]}

机构：

[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] MSC Natl Res Inst Oncol, Krakow, Poland

[3] Univ Perugia, Azienda Osped Santa Maria Terni, Terni, Italy

[4] Minist Interior & Adm Hosp, Dept Hematol, Warmian Masurian Canc Ctr, Olsztyn, Poland

[5] Univ Navarra, Dept Haematol, Pamplona, Spain

[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Hematol, Barcelona, Spain

[7] Ohio State Univ, Wexner Med Ctr, Arthur G James Comprehens Canc Ctr, Dept Internal Med, Columbus, OH 43210 USA

[8] Ludwig Maximilians Univ Hosp, Munich, Germany

[9] Univ Wurzburg, Dept Pathol, Wurzburg, Germany

[10] MomorphoSys AG, Planegg, Germany

[11] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159983

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6596 / 6598

页数：3

共 50 条

[1] Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study
Duell, Johannes
Abrisqueta, Pau
Andre, Marc
Augustin, Marinela
Gaidano, Gianluca
Gonzalez Barca, Eva
Jurczak, Wojciech
Kalakonda, Nagesh
Liberati, Anna Marina
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S433 - S434
[2] EL-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years
Duell, Johannes
Jurczak, Wojciech
Liberati, Anna Marina
Halka, Janusz
Carbo, Esther Pena
Abrisqueta, Pau
Maddocks, Kami J.
Dreyling, Martin
Rosenwald, Andreas
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S375 - S375
[3] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
Saverno, Kimberly
Savill, Kristin M. Zimmerman
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Gordon, Sarah
Amoloja, Theresa
Llorente, Mae
Epperla, Narendranath
Nastoupil, Loretta J.
[J]. BLOOD, 2023, 142
[4] Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Duell, Johannes
Abrisqueta, Pau
Andre, Marc
Gaidano, Gianluca
Gonzales-Barca, Eva
Jurczak, Wojciech
Kalakonda, Nagesh
Liberati, Anna Marina
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Kuffer, Christian
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
[J]. REVISTA CHILENA DE LITERATURA, 2024, (109):
[5] Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Duell, Johannes
Abrisqueta, Pau
Andre, Marc
Gaidano, Gianluca
Gonzales-Barca, Eva
Jurczak, Wojciech
Kalakonda, Nagesh
Liberati, Anna Marina
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Kuffer, Christian
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
[J]. HAEMATOLOGICA, 2024, 109 (02) : 553 - 566
[6] Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Dull, Johannes
Maddocks, Kami J.
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin H.
Menne, Tobias
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet Vijay
Salles, Gilles A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Salles, Gilles
Dlugosz-Danecka, Monika
Ghesquieres, Herve
Jurczak, Wojciech
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
[8] Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
Abdulhaq, Haifaa
Hwang, Andrew
Mahmood, Omar
[J]. ONCOTARGETS AND THERAPY, 2023, 16 : 617 - 629
[9] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
Lu, Q.
Huang, H.
Tang, S.
Wang, Y.
Yang, D-H
[J]. DRUGS OF TODAY, 2021, 57 (09) : 571 - 580

← 1 2 3 4 5 →